Molecular diagnostics provider, Qiagen, has acquired UK-based DxS Ltd, one of the leading companies in the companion diagnostic kits field in a deal valued at US$130 M. The new entity would become the world’s leading provider of sample and assay technologies in companion diagnostics and biomarker research for the personalized healthcare segment.